RxSight has withdrawn its full-year 2026 financial guidance as it pivots strategy following a 19% year-over-year drop in product sales and a new collaboration with Alcon. Second-quarter total revenue reached $33.7 million, including $6.5 million from the Alcon partnership, while product sales excluding that collaboration fell to $27.2 million. Light Adjustable Lens unit volumes declined 9% to 24,917, and gross margin excluding Alcon revenue slipped to 71.2% from 74.9% a year earlier. The company reported a net loss of $12.1 million, or $0.29 per share, and ended the quarter with approximately $209 million in cash and short-term investments, plus a $60 million upfront payment from Alcon received after the quarter closed. President and CEO Aziz Mottiwala said the guidance withdrawal allows a thorough business assessment without prior constraints, with formal guidance expected to resume in early 2027.
Rxsight IncWithdraws 2026 guidance after 19% product sales drop and net loss.
Alcon AGAlcon partnership provides $6.5M revenue and $60M upfront payment.
